Please assess the completion status of the following clinical trial:

Trial Title: Reversing Type 1 Diabetes After it is Established

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be \> 12 years \< 45~* Must have a diagnosis of T1D of greater than 4 months duration, with an upper limit of 2 years, Now only recruiting for those diagnosed greater than 1 year but less than 2 years.~* Must have at least one diabetes-related autoantibody present (e.g., islet cell autoantigen (ICA), GAD, ZnT8, or islet antigen 2 (IA2) autoantibodies)~* Must have stimulated C-peptide levels ≥ 0.1 pmol/ml (0.3ng/mL) when measured during a mixed meal tolerance test (MMTT), conducted at least 4 months from diagnosis of diabetes, and within 8 weeks of randomization~* Must be EBV PCR negative within two weeks of randomization if EBV seronegative at screening~* Be at least 6 weeks from last live immunization~* Be willing to forgo live vaccines for 3 months following last dose of study drug~* Be willing to comply with intensive diabetes management~* Normal screening values for complete blood count (CBC), renal function and electrolytes (CMP).~Exclusion Criteria:~* Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (\< 3,000 leukocytes /μL), neutropenia (\<1,500 neutrophils/μL), lymphopenia (\<800 lymphocytes/μL), or thrombocytopenia (\<125,000 platelets/μL).~* Have a chronic infection at time of randomization~* Have a positive PPD~* Be currently pregnant or lactating, or anticipate getting pregnant within the next two years~* Require use of other immunosuppressive agents~* Have serologic evidence of current or past HIV, Tuberculosis, Hepatitis B or Hepatitis C infection~* Have any complicating medical issues or abnormal clinical laboratory results that interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, chronic obstructive pulmonary disease (COPD), sickle cell disease, neurological, or blood count abnormalities (e.g., lymphopenia, leukopenia, or thrombocytopenia)~* Have a history of malignancies~* Evidence of liver dysfunction with angiotensin sensitivity test (AST) or ALT greater than 3 times the upper limits of normal~* Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal~* Vaccination with a live virus within the last 6 weeks~* Current use of non-insulin pharmaceuticals that affect glycemic control~* Active participation in another T1D treatment study in the previous 30 days~* Known allergy to G-CSF or ATG~* Prior treatment with ATG or known allergy to rabbit derived products~* Any condition that in the investigator's opinion, may adversely affect study participation or may compromise the study results

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Anti-Thymocyte Globin plus pegylated GCSF (Type: EXPERIMENTAL): Subjects will receive an infusion of Anti-Thymocyte Globin (ATG) followed by 6 doses of pegylated GCSF every 2 weeks for 10 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Saline infusion will be given on both Day 1 and Day 2 followed by placebo injection given in identical volumes in identical syringes in the identical subcutaneous manner

Based on this trial design, predict the completion outcome and termination type (if applicable).